| Bioactivity | TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC50: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKAG595R, TRKAF589L, TRKAG667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties[1]. |
| Invitro | TRK-IN-29 对 Km-12, Ba/F3-TRKAG595R, and Ba/F3-TRKAG667C 细胞表现出较好的抗增殖效果， IC50 值分别为 0.3, 4.7, and 9.9 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> TRK-IN-29 相关抗体: |
| Formula | C19H17F3N6O |
| Molar Mass | 402.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qiaohua Qin, et al. Discovery of novel indazole derivatives as second-generation TRK inhibitors. European Journal of Medicinal Chemistry. Available online 1 July 2024, 116640, et al. |